Abstract:BackgroundNivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks interaction with its PD-L1 and PD-L2. This binding releases PD-1 pathway-mediated immune responses against tumour cells. Nivolumab has demonstrated efficacy in non-small-cell lung cancer (NSCLC), renal cancer, and head and neck cancer in monotherapy. Also, in metastatic melanoma in monotherapy or combined with ipilimumab. The toxicity grade was classified by Common Terminology Criteria for Adverse Effects v.4 (CTCAE): grade… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.